Assessment of in vitro and in vivo effect of Quercetin 3-Glucoside, Oxyresveratrol and Quercetin O-Hexoside against Leishmania tropica

Abstract The aim was to scrutinize the in vivo and in vitro activities against Leishmania tropica with compounds of Oxyresveratrol, Quercetin O-Hexoside, and Quercetin 3-Glucoside. The in vitro outcomes against Leishmania were analyzed for 24-48 hours on L. tropica KWH23 promastigotes with compounds materials having 50 - 200 µg/mL concentration with negative control and standard drug Amphotericin B. The compounds were analyzed in L. tropica infected BALB/c mice against Leishmania tropica. The Quercetin 3-Glucoside shows mean inhibition of extracellular promastigotes after 48 hours at 50, 100, 150, 200 µg/mL were 91.02 ± 0.12, 94.50 ± 0.07, 96.15 ± 0.17 and 97.01 ± 0.08 % respectively. In BALB/c mice, the intracellular amastigotes were 91% cured at 200 µg/mL and mean lesion size decreased to 0.41 ± 0.21 mm (p < 0.01). The result shows that Quercetin 3-Glucoside possesses significant anti-leishmanial activity.

Planejamento e desenvolvimento de novos compostos com atividade frente a Leishmania spp: Síntese, avaliação da atividade e toxicidade de derivados 5-nitro-2-furfurilidênicos e estudos de relações estrutura-atividade / Design of new compounds against Leishmania spp: synthesis, biological evaluation and toxicity of 5-nitro-2-furfurylidene derivates and structure-activity relationship studies

A leishmaniose é uma zoonose de ampla distribuição mundial, causada pelos parasitas tripanossomatídeos do gênero Leishmania. Infelizmente, o arsenal terapêutico disponível é precário, mas vê-se crescente o interesse científico pela busca do potencial de derivados nitroheterocíclicos como alternativas terapêuticas. Nesse contexto, este trabalho analisou o potencial de derivados 5-nitro-2-furfurilidênicos contra diferentes cepas de Leishmania, assim como investigou um possível modo de ação para esta classe de nitrocompostos. Para tal, a quimioteca foi sintetizada de acordo com publicações prévias do grupo. O potencial de inibição de crescimento das culturas de promastigotas de L. (L.) infantum (Linf) e L. (L.) major (Lmaj) foi determinado, utilizando miltefosina (MILT) (Linf - IC50: 8,28±0,33 µM), anfotericina B (AMB) (Linf - IC50: 0,02±0,002 µM) e nifurtimox (NFX) (Lmaj - IC50: 3,5±0,09 µM) como referência. A maioria dos compostos apresentaram maior potencial que as referênias, destacando o composto 40 (Linf - IC50: 0,2±0,019 µM/ Lmaj - IC50: 0,087 ± 0,001 µM) como mais eficaz. Contra as formas amastigotas intracelulares, para Linf os compostos 40, 13 e 15 foram mais eficazes em reduzir a carga parasitária dos macrófagos infectados que fármacos de referência. Para Lmajor, o composto 40 (IC50: 0,006 ± 0,0003 µM) foi mais ativo que o NFX (IC50: 2,15 ± 0,01 µM). Também foi determinada a atividade da quimioteca frente a enzima nitrorredutase (NTR1), utilizando cepas de T. brucei superexpressantes de NTR1, e os compostos analisados foram até 18 vezes mais eficazes que à cepa wild-type. Ademais, a partir da análise exploratória de dados por análise de componentes principais (PCA) e de grupamentos hierárquicos (HCA), foi reconhecida a influência das propriedades relacionadas com o equilíbrio hidrófilo-lipófilo e da natureza estérica/geométrica das moléculas para atividade anti-Leishmania

Leishmaniasis is a worldwide zoonosis caused by trypanosomatid parasites of the genus Leishmania. Unfortunately, the available therapeutic arsenal is precarious, but there is growing scientific interest in searching the potential of nitroheterocyclic derivatives as therapeutic alternatives. In this context, this work analyzed the potential of 5-nitro-2-furfurylidene derivatives against different Leishmania strains, as well as investigated the potential mode of action for this nitro compounds class. To this end, the chemolibrary was synthesized according to our group's previous publications. The growth inhibitory potential potential for promastigote cultures of L. (L.) infantum (Linf) and L. (L.) major (Lmaj) was determined using miltefosine (MILT) (Linf - IC50: 8.28±0.33 µM), amphotericin B (AMB) (Linf - IC50: 0.02±0.002 µM) and nifurtimox (NFX) (Lmaj - IC50: 3.5±0.09 µM) as reference. Most of the compounds were more potent than the references, highlighting compound 40 (Linf - IC50: 0.2±0.019 µM/ Lmaj - IC50: 0.087 ± 0.001 µM) as the most effective. Against intracellular amastigote, for Linf, compounds 40, 13 and 15 were more effective in reducing the parasite load of infected macrophages than reference drugs. For Lmajor, compound 40 (IC50: 0.006 ± 0.0003 µM) was more active than NFX (IC50: 2.15 ± 0.01 µM). The activity against nitroreductase (NTR1) enzyme was determined using overexpressing NTR1 mutant T. brucei strains, and the analyzed compounds were up to 18 times more effective than wild-type. Furthermore, exploratory data analysis using principal component analysis (PCA) and hierarchical clustering (HCA) methods were used. The influence of properties related to the hydrophiliclipophilic balance and the steric/geometric nature of the molecules was associated with the anti-Leishmanial activity

Correlation study and histopathological description of intestinal alterations in dogs infected with Leishmania infantum / Estudo de correlação e descrição histopatológica das lesões intestinais de cães infectados com Leishmania infantum

Abstract The aim of this work was a correlation study and histopathological description of alterations associated with the presence of Leishmania infantumamastigote in the intestinal wall of dogs infected with canine visceral leishmaniasis (CVL). Three groups were used: G1 (n = 8), comprising naturally infected dogs with CVL with amastigotes of L. infantum in the small and large intestines; G2 (n = 9), infected dogs with CVL, without intestinal amastigotes; and G3 (n = 3), uninfected dogs. Histochemistry and immunohistochemistry methods were used for histopathology and amastigotes identification. 47.1% (8/17) of dogs from G1 group had amastigotes in the mucosa, submucosa and muscle layers of the small and large intestines and it was observed a prominent inflammatory reaction characterized by chronic infiltration of mononuclear cells: macrophages, lymphocytes and plasma cells. Comparison between the groups showed only a significant difference in relation to mucosal microscopic structural alterations in dogs from G1 in relation to G2 and G3. Parasite burden showed significant correlations with the microscopic alterations and clinical status of dogs in G1. By the conclusion, the inflammatory reactions caused by the parasites in the intestines might have contributed towards alterations in digestive processes, worsening the dogs’ clinical status of CVL.

Resumo O objetivo foi realizar um estudo de correlação e descrição histopatológica das lesões associadas à presença de amastigotas de Leishmania infantum na parede intestinal de cães infectados com leishmaniose visceral canina (LVC). Os cães foram subdivididos em três grupos: G1 (n = 8) cães naturalmente infectados com LVC e com amastigotas de L. infantum no intestino; G2 (n = 9) com LVC, mas sem o parasitismo intestinal; e G3 (n = 3) cães não infectados. Métodos histoquímicos e imunoistoquímicos foram utilizados para a histopatologia e a identificação das amastigotas, respectivamente. 47,1% (8/17) dos cães infectados (grupo G1) apresentavam formas amastigotas na mucosa, submucosa e camada muscular do intestino delgado e grosso, destacando-se uma reação inflamatória caracterizada por infiltrado crônico de células mononucleares; macrófagos, linfócitos e plasmócitos. Observou-se uma diferença significativa somente com relação às alterações estruturais microscópicas intestinais nos cães do G1 quando comparadas com G2 e G3. A intensidade parasitária intestinal teve correlação significativa com as alterações microscópicas e os sinais clínicos dos cães do G1. Concluiu-se que as amastigotas de L. infantum por causarem reações inflamatórias na parede intestinal dos cães podem ter contribuído para as alterações dos processos digestórios, agravando ainda mais o quadro clínico dos animais.

Leishmania Amastigotes Induced Remission of Cutaneous Leishmaniasis, Psoriasis, Psoriatic Arthritis and Related Diseases.

Amastigotes from L(L) amazonensis (La); L(L) venezuelensis (Lv); L(V) brasiliensis (Lb) and L(L)chagasi(Lch) were cultured axenically in a liquid culture medium (O’Daly’s medium). Patients from a cutaneous leishmaniasis (CL) endemic and hyperendemic regions in Venezuela, receiving different treatments were followed up for 6 years. Remission of lesions (weeks) were: Spontaneous remission (SR): 7; Glucantime® (Glu) chemotherapy: 9; Immunotherapy with La, Lv, Lb, Lch amastigotes Tosyl-Lysil-Chloromethyl-Ketone (TLCK) treated and Nonidet P-40 (NP-40) extracted (AS100-1VT): 7. While vaccinating subjects for CL protection, we observed 100% clinical remission of a psoriatic lesion in one subject. In an open trial, 2,770 subjects showed baseline psoriasis area and severity index (PASI) compared with post-treatment values as follows: PASI 100, 23%; PASI 75, 45%; PASI 50, 13%; PASI 10, 9% and <PASI 10, 3% of patients, without serious adverse events. Similar results were obtained with AS100-2 La, Lv, Lb and Lch monovalent vaccines. After treatment with AS100-1VT, subjects with psoriatic arthritis (PsA) decreased in arthritis score, tender joints counts and nail changes; the highest decreased in the PASI 100 group. The vaccines induced cellular immunity with absence of humoral antibody responses. Lymphocyte subsets (LS) in peripheral blood mononuclear cells (PBMC) decrease as PASI increased migrating from the blood to the skin/joints. After vaccine treatment the LS migration is stopped explaining remission of lesions. Purified Leishmania antigenic fractions (AS200) induced linear delayed type hypersensitivity reactions (DTH) in guinea pigs. A DBA-1 mouse collagen induced arthritis (CIA) model with AS200 treatment had the least amount of forepaw inflammation and the lowest arthritis scores, lower than dexamethasone. The vaccines AS100-1VT, AS100-2 and AS200 were not immunosuppressors, but immunomodulators decreasing inflammatory cytokines. The aim of this review is to explain the serendipity discovery of leishmania parasites inducing remission of psoriasis and related diseases, unprecedented discovery in the scientific literature.

In vitro efficacy of Coriandrum sativum, Lippia sidoides and Copaifera reticulata against Leishmania chagasi / Eficácia in vitro de Coriandrum sativum, Lippia sidoides e Copaifera reticulata sobre Leishmania chagasi

The increased incidence of visceral leishmaniasis (VL) in Brazil is due to a lack of effective disease control measures. In addition to that, no effective treatment exists for canine VL in response to synthetic drugs. Thus, the objective of this study was to evaluate the effect of the essential oils of Coriandrum sativum and Lippia sidoides, and oleoresin from Copaifera reticulata, on Leishmania chagasi promastigotes and amastigotes. We also examined the toxicity of these treatments on the murine monocyte cell line RAW 264.7. To determine the IC50 a MTT test (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) was performed on promastigotes, and an in situ ELISA assay was conducted on amastigotes. Here, we demonstrate that oleoresin from C. reticulata was effective against both promastigotes (IC50 of 7.88 µg.mL-1) and amastigotes (IC50 of 0.52 µg.mL-1), and neither of the two treatments differed significantly (p > 0.05) from pentamidine (IC50 of 2.149 µg.mL-1) and amphotericin B (IC50 of 9.754 µg.mL-1). Of the three plant oils tested, only oleoresin showed no toxicity toward monocyte, with 78.45% viability after treatment. Inhibition of promastigote and amastigote growth and the lack of cytotoxicity by C. reticulata demonstrate that oleoresin may be a viable option for analyzing the in vivo therapeutic effects of leishmanicidal plants.

O aumento na incidência da Leishmaníase Visceral (LV) no Brasil deve-se à ineficácia das medidas de controle da doença. Além disso, não há tratamento efetivo para LV canina com drogas sintéticas. Assim, o objetivo deste trabalho foi avaliar o efeito dos óleos essenciais de Coriandrum sativum e de Lippia sidoides e do óleo-resina de Copaiferareticulata sobre promastigotas e amastigotas de Leishmania chagasi e analisar o grau de toxicidade sobre células monocíticas murinas RAW 264.7. Para determinar a CI50 sobre promastigotas foi usado teste MTT (brometo de 3-[4,5-dimetil-tiazol-2-il]-2,5-difeniltetrazólio) e sobre amastigotas foi realizado imunoensaio in situ pela técnica de ELISA. Os resultados obtidos comprovaram que o óleo-resina de C. reticulata foi o mais eficaz contra as formas promastigotas (CI50 de 7,88 µg.mL-1) e amastigotas (CI50 de 0,52 µg.mL-1) e em nenhum dos dois testes diferiu do controle pentamidina que obteve CI50 de 2,149 µg.mL-1, no teste sobre promastigotas, e anfotericina B que obteve CI50 de 9,754 µg.mL-1, nos testes com amastigotas (p > 0.05). Quanto à citotoxicidade apenas o óleo-resina não apresentou toxicidade com 78,45% de monócitos viáveis. Os resultados obtidos sobre promastigotas e amastigotas e a ausência de citotoxicidade do óleo-resina de C. reticulata evidenciam que este óleo-resina pode ser viável para a análise de seus efeitos terapêuticos em testes in vivo.

Experimental chemotherapy with Allium sativum (Liliaceae) methanolic extract in rodents infected with Leishmania major and Leishmania donovani.

Background & objectives: Several plant products have been tested and found to possess antileishmanial activity. The present study was undertaken to establish whether methanolic extract of Allium sativum Linn has antileishmanial activity in comparison to standard drugs. Methods: Methanolic extract of A. sativum bulbs was screened for in vitro and in vivo antileishmanial activity against Leishmania major strain (NLB 145) and L. donovani strain (NLB 065). Pentostam® and Amphotericin B® were used as standard drugs. BALB/c mice and golden hamsters (Mesocricetus auratus) were used in in vivo studies on L. major and L. donovani respectively. Results: The extract exhibited very low cytotoxicity (IC50 >450 μg/ml) against Vero cells. The extract had significantly better (p <0.001) leishmanicidal activity against both species (IC50 34.22 μg/ml to L. major, 37.41 μg/ml to L. donovani) than Pentostam. However, the activity was significantly lower (p <0.001) than that of Amphotericin B against both the species. At a concentration of 250 μg/ml, the extract induced the production of 60 μM of nitric oxide, a ten-fold up-regulation in activated macrophages. The multiplication indices for L. major amastigotes treated in 100 μg/ml were significantly different (p <0.05). Treatment with the extract, daily for 28 days led to a significant reduction (p <0.05) in footpad swelling in BALB/c mice; similar activity noticed in the treatment with standard drugs. The Leishman-Donovan Units (LDU) for the extract treated animals were significantly higher (p <0.05) than those of standard drugs, but lower compared to the negative control. Interpretation & conclusion: Since the mechanism of action for the methanolic extract is apparently immunomodulatory, garlic compounds could be purified and tried as complementary medicine in the management of leishmaniases.

Actividad contra Trypanosoma cruzi, Leishmania chagasi y células de mamífero de nuevas N-bencil (2-furilmetil) cinamamidas / Activity against Trypanosoma cruzi, Leishmania chagasi and mammalian cells of new N-benzyl (2-furylmethyl) cinnamamides

Introducción: La quimioterapia contra la leishmaniasis y la enfermedad de Chagas es inefectiva, condición que agrava el problema de salud pública que estas enfermedades tropicales representan. Objetivo: Determinar la actividad de nuevas N-bencil (2-furilmetil) cinamamidas en las formas libres e intracelulares de Leismania chagasi y Trypanosoma cruzi y en células Vero y THP-1. Materiales y métodos: Los parásitos y las células fueron tratados con diferentes concentraciones de los compuestos y su actividad fue determinada microscópicamente y por ensayos de MTT en el caso de los parásitos y células de mamífero, respectivamente. Los resultados de actividad fueron expresados como la concentración que inhibe o destruye 50% o 90% de los parásitos o células. Resultados: Las N-arilalquilamidas 1, 2 y 5 fueron activos en epimastigotes de T. cruzi con actividades entre CI50 3,71-38,81 µM y CI90 entre 50,87-59,87 µM. El compuesto 2 presentó actividad en amastigotes intracelulares de L. chagasi con CI50 77,76 µM. Las amidas preparadas no presentaron toxicidad en células THP-1 y solo el compuesto 4 fue parcialmente tóxico en células Vero (CC50 65,9 ± 5,71 µM). Conclusiones: La baja toxicidad presentada por los compuestos 1, 2 y 5 y la actividad antiparasitaria mostrada soportan el diseño de nuevas moléculas relacionadas para ser evaluadas en sistemas in vitro e in vivo contra estas enfermedades parasitarias.

Introduction: The chemotherapy against leishmaniasis and Chagas disease is ineffective, a condition that is aggravating the public health problem caused by these tropical diseases. Objective: To determine the activity of new N-benzyl(2-furylmethyl) cinnamamides in the free and intracellular forms of Leishmania chagasi and Trypanosoma cruzi and Vero and THP-1 cells. Materials and Methods: The parasites and cells were treated with different concentrations of the compounds and the activity was determined microscopically and MTT assays in the case of parasites and mammalian cells. Antiparasitic activity of tested compounds was expressed as the concentration that inhibits or destroys 50% or 90% of parasites and cells. Results: The N-arylalkylamides 1, 2 and 5 were active against T. cruzi epimastigotes with a range of activities between IC50 3.71-38.81 ìM and IC90 between 50.87-59.87 ìM. The compound 2 was active on intracellular amastigotes of L. chagasi with IC50 77.76 ìM. The tested amides were not toxic to THP-1 cells; just only compound 4 resulted partially toxic on Vero cells (CC50 65.9 ± 5.71 ìM). Conclusions: The low toxicity and the antiparasitic activity showed by the cinnamanide compounds 1, 2 and 5 support the design of new related molecules in order to be evaluated on in vitro and in vivo systems for these parasitic diseases.

A century of research: what have we learned about the interaction of Trypanosoma cruzi with host cells?

Since the discovery of Trypanosoma cruzi and the brilliant description of the then-referred to "new tripanosomiasis" by Carlos Chagas 100 years ago, a great deal of scientific effort and curiosity has been devoted to understanding how this parasite invades and colonises mammalian host cells. This is a key step in the survival of the parasite within the vertebrate host, and although much has been learned over this century, differences in strains or isolates used by different laboratories may have led to conclusions that are not as universal as originally interpreted. Molecular genotyping of the CL-Brener clone confirmed a genetic heterogeneity in the parasite that had been detected previously by other techniques, including zymodeme or schizodeme (kDNA) analysis. T. cruzi can be grouped into at least two major phylogenetic lineages: T. cruzi I, mostly associated with the sylvatic cycle and T. cruzi II, linked to human disease; however, a third lineage, T. cruziIII, has also been proposed. Hybrid isolates, such as the CL-Brener clone, which was chosen for sequencing the genome of the parasite (Elias et al. 2005, El Sayed et al. 2005a), have also been identified. The parasite must be able to invade cells in the mammalian host, and many studies have implicated the flagellated trypomastigotes as the main actor in this process. Several surface components of parasites and some of the host cell receptors with which they interact have been described. Herein, we have attempted to identify milestones in the history of understanding T. cruzi- host cell interactions. Different infective forms of T. cruzi have displayed unexpected requirements for the parasite to attach to the host cell, enter it, and translocate between the parasitophorous vacuole to its final cytoplasmic destination. It is noteworthy that some of the mechanisms originally proposed to be broad in function turned out not to be universal, and multiple interactions involving different...

SÍNTESIS Y ACTIVIDADES LEISHMANICIDA Y CITOTÓXICA in vitro DE ANÁLOGOS 2-ARILQUINOLINAS / SYNTHESIS AND in vitro LEISHMANICIDAL AND CYTOTOXIC ACTIVITIES OF 2-STYRYLQUINOLINES ANALOGS

Actualmente la quimioterapia de la leishmaniasis es promisoria, sin embargo aun no se dispone de un medicamento adecuado. Varias quinolinas sustituidas han presentado actividad in vitro contra agentes causales de leishmaniasis cutánea, leishmaniasis visceral, tripanosomiasis africana y enfermedad de Chagas. En este trabajo se sintetizan seis 2-arilquinolinas derivadas de la galipeina mediante condensación de Perkin a partir de quinaldina y aldehídos aromáticos. La actividad leishmanicida se evalúa en amastigotes axénicos y la actividad citotóxica en células U-937. Todos los compuestos muestran ser activos contra leishmania panamensis pero también contra células mamíferas. Los compuestos estirilquinolinas 2-[(E)-2-(2,5-dimetoxifenil)etenil]quinolina (1), 2-[(E)-2-(2,3-dimetoxifenil)etenil]quinolina (2) y N-{4-[(E)-2-quinolin-2-iletenil]fenil}acetamida (3) son mas activos sobre amastigotes axénicos (CE50 = 3,7; 4,5 y 19,1μg/mL) e intracelulares (CE50 = 1,4; 1,8 y 1,7μg/mL), en comparación con los derivados hidrogenados 2-[2-(2,5-dimetoxifenil)etil]quinolina (1a), 2-[2-(2,3-dimetoxifenil)etil]quinolina (2a) y N-[4-(2-quinolin-2-iletil)fenil]acetamida (3a) (CE50= 31,1; 23,6 y 59,3μg/mL). Todos los compuestos muestran también actividad contra células U-937 con CE50 de 3,7; 6,2 y 4,5μg/mL para las estirilquinolinas 1, 2 y 3, respectivamente y CE50 de 16,0; 12,9 y 20,2μg/mL para los derivados hidrogenados 1a, 2a y 3a, respectivamente. Aunque el proceso de hidrogenación produjo una disminución tanto de la actividad leishmanicida como de la actividad citotóxica, la actividad leishmanicida mostrada por los compuestos de tipo 2-estirilquinolinas les confiere un potencial como moléculas candidatas para el desarrollo de compuestos anti-leishmania.

The search of new treatments for leishmaniasis is an active task nowadays, since there is a lack of non-toxic, cheap and non-resistant medication. In the literature several quinolines have shown in vitro activity against agents of cutaneous leishmaniasis, visceral leishmaniasis, African trypanosomiasis and Chagas diseases. Six 2-styrylquinolines derived from galipeine were synthesized by Perkin condensation of quinaldine with aromatic aldehydes. Leishmanicidal activity was estimated for leishmania panamensis at the amastigote form and cytotoxic activity against U-937 cells. All compounds showed activity against both L. panamensis and U-937 cells. (E)-2-(2,5-dimethoxyphenyl)ethenyl)quinoline (1), (E)-2-(2,3-dimethoxyphenyl)ethenyl)quinoline (2) and (E)-N-[4-(2-quinolin-2-yl-ethenyl)phenyl]acetamide (3) were more active against axenic (EC50= 3.7, 4.5 and 19.1μg/mL) and intracellular amastigotes (EC50= 1.4, 1.8 and 1.7μg/ml, respectively), in comparison with hydrogenated derivatives 2-[2-(2,5-dimethoxyphenyl)ethyl]quinoline (1a), 2-[2-(2,3-dimethoxyphenyl)ethyl]quinoline (2a) and N-[4-(2-quinolin-2-ylethyl)phenyl]acetamide (3a) (CE50= 31.1, 23.6 and 59.3μg/mL, respectively). All compounds were also active against the U-937 cells. Styrylquinolines 1, 2 and 3 showed a LC50 of 3.7, 6.2 and 4.5μg/mL, respectively and the hydrogenated derivatives 1a, 2a and 3a showed a LC50 of 16.0. 12.9 and 20.2μg/mL, respectively. Although hydrogenation reduced the leishmanicidal and cytotoxic activities, the activity showed against leishmania parasites suggests this compound series has potential as drug candidates for the treatment of leishmaniasis.

Analysis and chromosomal mapping of Leishmania (Leishmania) amazonensis amastigote expressed sequence tags

The characterization of expressed sequence tags (ESTs) generated from a cDNA library of Leishmania (Leishmania) amazonensis amastigotes is described. The sequencing of 93 clones generated new L. (L.) amazonensis ESTs from which 32 percent are not related to any other sequences in database and 68 percent presented significant similarities to known genes. The chromosome localization of some L. (L.) amazonensis ESTs was also determined in L. (L.) amazonensis and L. (L.) major. The characterization of these ESTs is suitable for the genome physical mapping, as well as for the identification of genes encoding cysteine proteinases implicated with protective immune responses in leishmaniasis.

Efecto de derivados de la tiadiazina sobre la capacidad infectiva de promastigotes de Leishmania amazonensis / Effects of thiadiazine derivatives on the infective capacity of Leishamia amazonensis promastigotes

Se evaluó la capacidad infectiva de promastigotes de Leishmania amazonensis al ser tratados con una serie de 10 derivados de la tiadiazina. Los parásitos fueron incubados durante 24 h con 1 o 0,1 mg/mL de cada compuesto y posteriormente, se infectaron macrófagos peritoneales de ratones BALB/c en cultivos. Todos los compuestos causaron una reducción de la capacidad infectiva de los parásitos mayor que 50 %. El producto T1O fue el que causó un mayor efecto, disminuyendo la infección en 92,8 % de infección.

The infective capacity of Leishmania amazonensis promastigotes was evaluated after they were treated with a series of 10 thiadiazine derivatives. The parasites were incubated for 24 hours with 1 or 0,1 mg/ml of each compound and then, peritoneal macrophages from BALB/c mice were infected in cultures. All the compounds managed to reduce the infective capacity of parasites by more than 50%. T10 product exhibited the highest effect since it reduced infection by 92,8%.